Efficient Designs in Phase I Trials in Oncology
Publié le
IDDI organized a webinar on Efficient Designs in Phase I oncology trials. The key learning objectives of this webinar were…
The Need for Better Endpoints: Towards a More Efficient Drug Development in Oncology
Publié le
IDDI organized a webinar on THE NEED FOR BETTER CLINICAL ENDPOINTS : TOWARDS A MORE EFFICIENT DRUG DEVELOPMENT IN ONCOLOGY The…
Ophthalmology Services
Publié le
Ophthalmology CRO IDDI is a leading global ophthalmology CRO offering biostatistics and eClinical solutions for ophthalmology studies. We have run nearly 100 trials in…
Clinical Validity Of Circulating Tumor Cells (CTC)
Publié le
Assessment of Clinical Validity of Circulating Tumor Cells (CTC) Quantification Clinical Validity Of Circulating Tumor Cells (CTC) In Patients With…
A Double Masked Minimization in Ophthalmology Study
Publié le
Phase II study conducted with a dose-escalation minimization A phase II ophthalmology study was conducted with a dose-escalation minimization to…
Flexible Study Design
Publié le
A Flexible Study Design with Randomization to Placebo The maximum tolerated dose of a new drug, supposed to alleviate some…
Discovering New Prognostic Biomarkers For Breast Cancer
Publié le
New prognostic biomarkers for breast cancer: A range of biological markers were analyzed by polymerase chain reaction and immunohistochemistry in…
Meta-Analysis To Assess Efficacy in Colorectal Cancer
Publié le
In this meta-analysis, tumor responses and survival were analyzed combining the data from the different trials using patient individual data. The…
Validation of a Genetic Signature For Women With Node-Negative Breast Cancer
Publié le
A 70-genetic signature was shown in a single institution to have prognostic value in patients with node-negative breast cancer. The…
Jumping Ahead to Phase III trial
Publié le
A new ophthalmic drug was going to enter a phase II dose-ranging trial in order to determine the dose to…